# Acute Sinusitis Market

> 急性鼻窦炎市场研究报告信息按治疗（盐水鼻喷雾剂、鼻用皮质类固醇、减充血剂、非处方止痛药、过敏针和抗生素）、按最终用户（医院和诊所及研究中心）、按诊断（鼻内窥镜检查、影像学检查、实验室检查和过敏测试）以及按地区（北美、欧洲、亚太和世界其他地区）–市场预测至2035年

- **Forecast Period:** 2025 - 2035
- **CAGR:** 6.92%
- **2024:** $ 2.32 Billion
- **2025:** $ 2.48 Billion
- **2035:** $ 4.84 Billion
- **Key Players:** GlaxoSmithKline (GB), Sanofi (FR), Bayer (DE), Merck & Co. (US), AstraZeneca (GB), Novartis (CH), Teva Pharmaceutical Industries (IL), Johnson & Johnson (US), AbbVie (US)

**Report ID:** MRFR/HC/4371-CR · **Pages:** 126 · **Author:** Vikita Thakur & Rahul Gotadki · **Last Updated:** August 11, 2026

**URL:** https://www.marketresearchfuture.com/reports/acute-sinusitis-market-5827

---

## Market Summary

## **Global Acute Sinusitis Market Overview**

Acute Sinusitis Market Size was valued at USD 2.15 Billion in 2023. The acute sinusitis market industry is projected to grow from USD 2.31 Billion in 2024 to USD 3.961 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 6.92% during the forecast period (2024 - 2032). Since acute sinusitis affects a large portion of the population worldwide, governments and businesses are collaborating to address the issue and offer better solutions, and government and business investments in technological advancements are raising the likelihood of a market expansion.

Additionally, rising demand for over-the-counter medicines and treatments, such as nasal corticosteroids and nasal sprays, is a significant market driver that is projected to propel market expansion in the years to come.

Source Secondary Research, Primary Research, _Market Research Future_ Database and Analyst Review

In May 2023, Zocdoc, the preeminent healthcare marketplace, made an announcement regarding its expansion to encompass urgent treatment. This development will assist patients in conveniently locating and scheduling both in-person and virtual treatments for over twelve thousand insurance types and over two hundred specialties. Through Zocdoc, it is now possible to schedule appointments online at over two hundred urgent care centers in twenty-two states. In fact, Urgent Care is one of the care categories on Zocdoc that is expanding the quickest, for both providers and patients.

Appointment requests for urgent care facilities increased by an average of 80% per month in 2023, while the number of new Zocdoc urgent care facilities increased by nearly 40% per month. Urgent care clinics are visited by Zocdoc patients seeking treatment for infections such as sinusitis.

In May 2023, the supplemental new drug application (sNDA) submitted by the pharmaceutical company Optinose for the approval of XHANCE, a treatment for chronic rhinosinusitis, was accepted for review by the U.S. Food and Drug Administration (FDA). A revolutionary drug-device combination, the XHANCE (fluticasone propionate) nasal spray combines the most popular nasal anti-inflammatory medication with the cutting-edge Exhalation Delivery System (EDS). The EDS was created to provide a novel method of medication delivery, specifically into the difficult-to-reach sinuses and sinonasal drainage systems.

The Prescription Drug User Fee Act (PDUFA) target objective date for the sNDA filing of the ReOpen Program is December 16, 2023. This date is based on the findings of two Phase 3 clinical studies involving patients diagnosed with chronic sinusitis.

## **Acute Sinusitis Market Trends**

Since children's sinuses are smaller and less formed, adults are more likely to acquire acute sinusitis than children. Sinusitis has an incidence of 15–40 episodes per 1,000 patients annually, according to studies, and accounts for 0.5% of all upper respiratory tract infections. Additionally, general practitioners identify acute sinusitis as the second most typical infectious condition. Nearly 35 million Americans suffer from acute sinusitis, which is more common among elderly persons (45 to 64 years of age), according to a WebMD LLC. (US) article from February 2021.

Acute sinusitis causes more than 15 million patients to visit doctors each year in the US. Furthermore, acute sinusitis has a yearly frequency of 6-15% around the world, according to the World Allergy Organisation. Therefore, it is anticipated that throughout the projected period, the rising incidence of acute sinusitis cases will propel the expansion of the  acute sinusitis market CAGR.

It is projected that a rising  trend in healthcare research and development expenditures will support market growth in the future. One of the main trends in the acute sinusitis industry is the emergence of biologics. Right now, omalizumab is the best solution. This drug has been approved for the treatment of severe allergic asthma in both the US and Europe. Omalizumab is being tested by researchers for its safety and effectiveness in treating chronic rhinosinusitis with nasal polyps. The  acute sinusitis market is predicted to grow as a result of the successful introduction of biologics like omalizumab.

Key firms across the globe are continuously increasing their spending on marketing and innovation as a result of a continued focus on cost management and increased process efficiency. Thus, driving the acute sinusitis market revenue.

## **Acute Sinusitis Market Segment Insights**

### **Acute Sinusitis Treatment Insights**

The  acute sinusitis market segmentation, based on treatment includes Saline Nasal Spray, Nasal Corticosteroids, Decongestants, OTC Pain Relievers, Allergy Shots and Antibiotics. The antibiotics segment dominated the market. In order to prevent more severe complications from bacterial acute sinusitis affecting the frontal, sphenoid, or ethmoid sinuses, antibiotics are advised. For a very long time, antibiotics like macrolides, cephalosporins, and penicillins have been advised.

### **Acute Sinusitis End-Users Insights**

The  acute sinusitis market segmentation, based on end-users, includes Hospitals & Clinics and Research Centers. The hospitals & clinics category generated the most income following a large number of patients seeking sinus treatment at the hospitals & clinics. The category is predicted to grow as a result of the rising incidence of acute sinusitis and the favorable reimbursement requirements. The ability to perform sophisticated sinus surgeries, the presence of technologically advanced medical equipment, and the infrastructure will all encourage segment expansion.

**Figure 1  Acute Sinusitis Market, by End-Users, 2023 & 2032 (USD Billion)**

****

**_Source Secondary Research, Primary Research, MRFR Database and Analyst Review_**

### **Acute Sinusitis Diagnosis Insights**

The  acute sinusitis market segmentation, based on diagnosis, includes Nasal Endoscopy, Imaging Test, Laboratory Test and Allergy Testing. The nasal endoscopy category generated the most income. A nasal endoscope, a specialized tool used during rhinoscopy, is used to view the sinus apertures and nasal passageways. The nasal mucosa, any abnormal growths or polyps, and any indications of inflammation or illness can all be seen clearly. The diagnosis and evaluation of the severity of acute sinusitis are aided by nasal endoscopy.

### **Acute Sinusitis Regional Insights**

By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. The North American acute sinusitis market area will dominate this market. North America's growth is boosted by its technological advancements in diagnostic services, rising spending, and simple accessibility to healthcare facilities. The prevalence of chronic diseases in the US is rising, which is accelerating market expansion there. The CDC estimates that 11% of Americans have acute sinusitis. An alarming pace of growth is being observed in the occurrence of acute sinusitis.

The government and the manufacturers are collaborating to give better treatment options and are heavily investing in technical breakthroughs to address this issue. In the years to come, market expansion is also predicted to be fueled by rising consumer demand for over-the-counter drugs such decongestants, nasal sprays, and nasal corticosteroids.

Further, the major countries studied in the market report are The US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

**Figure 2  ACUTE SINUSITIS MARKET SHARE BY REGION 2023 (USD Billion)**

****

**_Source Secondary Research, Primary Research, MRFR Database and Analyst Review_**

Europe acute sinusitis market accounts for the second-largest market share. The market is growing as a result of a well-established healthcare infrastructure and system, rising allergic rhinitis rates, and widespread product accessibility. The demand for its treatment is expected to rise due to the rising frequency of chronic sinusitis and the notable geographic variations in sinus-related disorders in European nations. Similarly, it is projected that the market will be similarly impacted by the rising prevalence of allergic rhinitis.

Approximately 20% of the population of Germany has at least one allergy, and only 10% of them choose to treat it properly, according to a study that was published in the World Allergy Organisation Journal. Further, the German acute sinusitis market held the largest market share, and the UK acute sinusitis market was the fastest growing market in the European region

The Asia-Pacific Acute sinusitis Market is expected to grow at the fastest CAGR from 2023 to 2032. Numerous acute and chronic diseases are becoming more commonplace at an alarming rate. India is home to 18% of the world's population with chronic respiratory disorders, according to the Institute for Health Metrics and Evaluation. Additionally, the market is expanding due to the growing demand for high-quality, affordable care. Aside from this, the region's simple access to treatment options and the rising number of people with sinusitis are fueling market expansion.

Moreover, China’s acute sinusitis market held the largest market share, and the Indian acute sinusitis market was the fastest growing market in the Asia-Pacific region.

**Acute Sinusitis Key Market Players & Competitive Insights**

Leading market players are investing heavily in research and development in order to expand their product lines, which will help the acute sinusitis market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their  footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, acute sinusitis industry must offer cost-effective items.

Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the  acute sinusitis industry to benefit clients and increase the market sector. In recent years, the acute sinusitis industry has offered some of the most significant advantages to market. Major players in the acute sinusitis market attempting to increase market demand by investing in research and development operations include Sanofi (France), Abbott (US), Bayer AG (Germany), Aurobindo Pharma (India), Bristol Myers Squibb (US), Merck KGaA (Germany), AstraZeneca (UK), Dr. Reddy’s Laboratories Ltd (India), Novartis AG (Switzerland), GlaxoSmithKline plc (UK) and Others.

Sanofi is a healthcare organisation that is involved in the development, production, marketing, and discovery of numerous drugs and vaccines. Its product line also includes human vaccinations for defence against a number of bacterial and viral infections, medications for the treatment of cancer, uncommon disorders, and multiple sclerosis, and other goods. Additionally, the company sells consumer healthcare items for women's health, digestion, allergy, cough, cold, flu, and sinuses, pain, and vitamins, minerals, and supplements. Sanofi's research and development efforts are concentrated on developing a combination therapy to boost treatment efficacy and on developing innovative biologic formulations to create precision medicines.

The healthcare corporation Novartis AG specializes in the development, production, and marketing of pharmaceutical goods for prescription and over-the-counter use as well as products for eye care. It offers medications for the treatment of ailments such infections, hematologic diseases, solid tumors, cancer, cardiovascular disease, dermatological issues, neurological disorders, ophthalmic and respiratory diseases, and others. Through Sandoz, the business sells biosimilars and generic medications. In August 2020, intranasal corticosteroids and Xolair have been approved by Novartis AG for the treatment of rhinosinusitis with nasal polyps.

**Key Companies in the acute sinusitis market include**

**Acute Sinusitis Industry Developments**

**_February 2022 _**_Olympus, a leader in developing and distributing ground-breaking solutions for medical and surgical procedures, declared that their CELERISTM single-use sinus debride system has been approved by the FDA and will soon be offered for purchase. In general ENT and sinus/rhinology procedures, the CELERIS system is made to cut, coagulate, debride, and remove thin bone and soft tissue._

**_August 2021 _**_When intranasal corticosteroids (INC) alone are not sufficient to address severe chronic rhinosinusitis with nasal polyps in patients 18 years of age and older, the European Commission (EC) has approved the use of Xolair (omalizumab) as an adjunctive therapy._

**_July 2021 _**_The Food and Drug Administration (FDA) has approved Nucala (mepolizumab) as a treatment for people with chronic rhinosinusitis and nasal polyps, according to GlaxoSmithKline (GSK). This is a new indication for the interleukin-5 (IL-5)-targeting monoclonal antibody mepolizumab._

## **Acute Sinusitis Market Segmentation**

### **Acute Sinusitis Treatment Outlook (USD Billion, 2018-2032)**

### **Acute Sinusitis End Users Outlook (USD Billion, 2018-2032)**

### **Acute Sinusitis Diagnosis Outlook (USD Billion, 2018-2032)**

### **Acute Sinusitis Regional Outlook (USD Billion, 2018-2032)**

## Market Drivers

### Increase in Healthcare Expenditure

各个地区医疗支出的上升趋势可能会促进全球急性鼻窦炎行业的发展。随着政府和私人实体分配更多资源用于医疗，医疗服务和治疗的可及性得以改善。这一资金的增加可以导致医疗基础设施的提升、更好的诊断设施以及更有效的急性鼻窦炎治疗选择。市场数据显示，医疗支出较高的地区往往报告更好的健康结果，包括未治疗鼻窦炎病例的发生率较低。因此，随着医疗支出的持续增加，预计急性鼻窦炎治疗市场将经历显著增长，受益于改善的护理可及性和创新的治疗方式。

### Expansion of Pharmaceutical Offerings

专门针对急性鼻窦炎的制药产品扩展有望推动全球急性鼻窦炎行业的发展。随着持续的研究和开发努力，制药公司越来越专注于创造新的药物，以解决鼻窦炎的根本原因。这包括新型[抗生素](https://www.marketresearchfuture.com/reports/antibiotics-market-8447)、抗炎药物和鼻用喷雾剂的开发，旨在有效缓解症状。市场数据显示，这些新产品的推出可能会增强患者可用的治疗选择，从而增加整体市场需求。随着更有效和针对性的疗法的出现，医疗提供者将拥有更广泛的工具来管理急性鼻窦炎，可能会改善患者的结果和满意度。

### Rising Awareness of Sinusitis Symptoms

对鼻窦炎相关症状和并发症的认识不断提高，似乎是全球急性鼻窦炎行业的一个关键驱动因素。随着个人对这种疾病的了解加深，他们更有可能寻求医疗帮助，从而导致更高的诊断率。这种提高的认识得到了各种健康宣传活动和教育计划的支持，旨在向公众普及鼻窦炎的信息。因此，对有效治疗选择的需求可能会增加，从而推动市场增长。此外，急性鼻窦炎的流行预计会影响全球数百万人，人口中有相当一部分经历复发性发作。这一趋势表明，随着意识的持续提高，急性鼻窦炎治疗市场将相应扩大。

### Technological Innovations in Diagnostic Tools

诊断工具的技术进步可能在塑造全球急性鼻窦炎行业中发挥关键作用。先进成像技术和即时检测等创新正在提高鼻窦炎诊断的准确性和速度。这些发展不仅促进了及时治疗，还改善了患者的结果。例如，便携式成像设备的引入使医疗提供者能够更高效地诊断鼻窦炎，可能会增加临床环境中的患者流量。随着诊断准确性的提高，预计将有更多个体被诊断和治疗急性鼻窦炎，从而推动市场增长。人工智能在诊断过程中的整合可能进一步简化操作，使医疗专业人员更容易识别和管理鼻窦炎病例。

### Growing Demand for Minimally Invasive Treatments

对微创治疗选择的日益偏好正在成为全球急性鼻窦炎行业的重要驱动因素。患者越来越倾向于选择恢复时间较短和并发症风险较低的治疗。这一趋势在气球鼻窦成形术等程序的日益采用中显而易见，由于其有效性和微创性而受到欢迎。市场数据显示，对这些程序的需求正在上升，因为它们提供了传统外科方法的可行替代方案。随着医疗提供者继续采用这些创新技术，急性鼻窦炎治疗市场预计将扩大。这一向较少侵入性选择的转变与医疗领域的更广泛趋势相一致，患者中心的方法正变得越来越受到重视。

## Future Outlook

预计全球急性鼻窦炎市场将在2025年至2035年期间以6.92%的年均增长率增长，推动因素包括发病率增加、治疗选择的进步和医疗支出的上升。

到2035年，市场预计将实现显著增长，反映出不断变化的医疗动态。

## Segment Insights

### 按治疗方式：鼻用皮质类固醇（最大）与生理盐水鼻喷雾（增长最快）

在全球急性鼻窦炎市场中，治疗细分市场展示了多个关键产品之间的市场份额分布。鼻用[皮质类固醇](https://www.marketresearchfuture.com/reports/corticosteroids-market-43141)目前占据最大的市场份额，因为它们在减少炎症和缓解症状方面的有效性，使其成为医疗提供者的首选。相比之下，生理盐水鼻喷雾作为一种快速增长的替代品，因其非药物益处和安全性而受到青睐，导致消费者对自然疗法的偏好增加。该细分市场的增长趋势受到对鼻窦炎管理意识提高和对提供症状缓解的非处方解决方案偏好的影响。随着患者寻求更快的治疗途径，像减充血剂和非处方止痛药这样的产品正在获得关注。此外，创新配方和联合疗法的引入预计将进一步推动该细分市场的增长，解决急性鼻窦炎的症状和潜在原因。

鼻用皮质类固醇（主导）与生理盐水鼻喷雾（新兴）

由于其强效的抗炎特性和在管理鼻窦炎症状方面的临床有效性，鼻用皮质类固醇被认为是全球急性鼻窦炎市场中的主导治疗选择。这些皮质类固醇有助于减少鼻腔阻塞并改善整体鼻窦功能，使其成为治疗方案中的基础。另一方面，生理盐水鼻喷雾被定位为一种新兴产品，因其温和的鼻部护理方法而日益受到欢迎。越来越多的患者选择生理盐水喷雾，因为它们提供了一种自然的方式来滋润鼻腔并冲洗刺激物，而没有与药物相关的副作用。这两种治疗方法满足不同患者的需求，皮质类固醇适用于需要更强症状管理的患者，而生理盐水喷雾则吸引那些优先考虑整体方法的消费者。

### 按最终用户：医院（最大）与研究中心（增长最快）

在全球急性鼻窦炎市场中，医院作为最大的最终用户，因其高患者量和综合护理设施而显著主导该领域。医院提供专业治疗和广泛资源的能力使其能够占据相当大的市场份额，成为管理急性鼻窦炎病例的关键参与者。另一方面，研究中心正在获得关注，因其专注于创新治疗和疗法，使其在塑造未来市场动态方面成为关键参与者。随着对急性鼻窦炎及其治疗选择的认识提高，医院和研究中心都经历了独特的增长趋势。医院正在扩大其设施和人员，以满足对鼻窦炎护理日益增长的需求，而研究中心则利用技术和临床研究的进步来推动新的治疗方案的制定。这种双重关注有助于形成一个支持性生态系统，使两类最终用户都能蓬勃发展，尽管每个用户从不同的战略视角接近市场。

医院（主导）与研究中心（新兴）

医院作为全球急性鼻窦炎市场中的主导最终用户细分，提供全面的护理和专业服务，满足大量患者的人口统计需求。它们丰富的资源和多学科团队使其能够有效管理复杂的鼻窦炎病例，并促进与耳鼻喉科和过敏医学专家的合作。相反，研究中心代表了这一领域中的新兴细分，致力于创新和新治疗策略的开发。这些中心专注于临床试验和突破性治疗的制定，通常与医院和制药公司合作，以快速将这些创新推向市场。医院的既有基础设施与研究中心的创新方法之间的相互作用为急性鼻窦炎管理的增长和进步创造了一个动态环境。

### 按诊断方式：鼻内镜检查（最大）与影像学检查（增长最快）

全球急性鼻窦炎市场展示了多样化的诊断方法，鼻内镜检查目前占据最大的市场份额。这种技术能够直接观察鼻腔和鼻窦，从而实现准确的诊断。影像学检查，特别是CT和MRI扫描，作为重要的贡献者，保持着稳定的市场份额。实验室检查和过敏测试也发挥着重要作用，尽管相对比例较小。该细分市场的增长主要受到对慢性鼻窦炎认识提高和诊断技术进步的推动。鼻内镜检查因其有效性和精确性而仍然是一个基础，而影像学检查则因影像技术的进步而迅速获得关注，使得更快、非侵入性的评估成为可能。对准确和及时诊断的需求正在有利地改变市场动态，向这些方法倾斜。

鼻内镜检查：主导与过敏测试：新兴

鼻内镜检查作为全球急性鼻窦炎市场中的主导诊断方法，提供了对鼻窦解剖的全面洞察，使其成为医生的首选。对于症状反复的患者尤其有价值，提供即时结果以指导进一步管理。另一方面，过敏测试作为一个关键细分正在崛起，识别可能加重鼻窦炎症状的过敏原。这种方法不仅支持鼻窦炎的诊断，还扩展到为患者制定个性化治疗计划。这两种诊断工具的相互作用突显了急性鼻窦炎管理不断发展的格局，其中全面评估为改善患者结果铺平了道路。

## Regional Market Share Analysis

根据地区，研究提供了北美、欧洲、亚太地区和世界其他地区的市场洞察。北美急性鼻窦炎市场将主导该市场。北美的增长得益于其在诊断服务方面的技术进步、支出增加和医疗设施的便利可及性。美国慢性疾病的流行率上升，加速了市场的扩展。CDC估计，11%的美国人患有急性鼻窦炎。急性鼻窦炎的发生率正在以惊人的速度增长。

政府和制造商正在合作提供更好的治疗选择，并在技术突破方面进行大量投资以解决这一问题。预计在未来几年，消费者对非处方药物（如减充血剂、鼻喷雾剂和鼻用皮质类固醇）的需求上升也将推动市场扩展。

此外，市场报告中研究的主要国家包括美国、加拿大、德国、法国、英国、意大利、西班牙、中国、日本、印度、澳大利亚、韩国和巴西。

**图2 急性鼻窦炎市场按地区的市场份额2023年（亿美元）**

**_来源：二次研究，初级研究，MRFR数据库和分析师评审_**

欧洲急性鼻窦炎市场占据第二大市场份额。由于完善的医疗基础设施和系统、过敏性鼻炎发病率上升以及产品的广泛可及性，市场正在增长。由于慢性鼻窦炎的发病率上升以及欧洲国家在鼻窦相关疾病方面显著的地理差异，预计对其治疗的需求将上升。同样，过敏性鼻炎的流行率上升也预计将对市场产生类似影响。

根据世界过敏组织期刊发布的一项研究，德国约20%的人口至少有一种过敏，而只有10%的人选择适当治疗。此外，德国急性鼻窦炎市场占据最大市场份额，而英国急性鼻窦炎市场是欧洲地区增长最快的市场。

亚太地区急性鼻窦炎市场预计将在2023年至2032年期间以最快的CAGR增长。急性和慢性疾病的发生率以惊人的速度上升。根据健康指标和评估研究所的数据，印度有18%的人口患有慢性呼吸系统疾病。此外，由于对高质量、经济实惠的护理需求增加，市场正在扩展。除此之外，该地区对治疗选择的便利可及性和患有鼻窦炎的人数增加也在推动市场扩展。

此外，中国的急性鼻窦炎市场占据最大市场份额，而印度的急性鼻窦炎市场是亚太地区增长最快的市场。

## Competitive Benchmarking

领先的市场参与者正在大力投资于研发，以扩展其产品线，这将进一步推动急性鼻窦炎市场的增长。市场参与者还采取多种战略活动来扩大其市场足迹，重要的市场发展包括新产品发布、合同协议、并购、增加投资和与其他组织的合作。为了在竞争激烈和不断增长的市场环境中扩展和生存，急性鼻窦炎行业必须提供具有成本效益的产品。
在急性鼻窦炎行业中，制造本地化以降低运营成本是制造商用来惠及客户并增加市场份额的关键商业策略之一。近年来，急性鼻窦炎行业为市场提供了一些最重要的优势。急性鼻窦炎市场的主要参与者包括：赛诺菲（法国）、雅培（美国）、拜耳（德国）、阿罗宾多制药（印度）、百时美施贵宝（美国）、默克KGaA（德国）、阿斯利康（英国）、德克瑞实验室（印度）、诺华（瑞士）、葛兰素史克（英国）等，试图通过投资研发活动来增加市场需求。
赛诺菲是一家医疗组织，涉及多种药物和疫苗的开发、生产、营销和发现。其产品线还包括针对多种细菌和病毒感染的防御性人用疫苗、癌症、罕见疾病和多发性硬化症的治疗药物及其他产品。此外，该公司还销售女性健康、消化、过敏、咳嗽、感冒、流感和鼻窦、疼痛、维生素、矿物质和补充剂的消费者保健产品。赛诺菲的研发工作集中在开发组合疗法以提高治疗效果和开发创新生物制剂以创造精准医学。
医疗公司诺华AG专注于处方和非处方药物以及眼科产品的开发、生产和营销。它提供用于治疗感染、血液疾病、实体肿瘤、癌症、心血管疾病、皮肤病、神经系统疾病、眼科和呼吸系统疾病等的药物。通过Sandoz，该公司销售生物类似药和仿制药。
在8月，诺华AG已批准鼻用皮质类固醇和Xolair用于治疗18岁及以上患者的伴有鼻息肉的重度慢性鼻窦炎。

## Recent News & Developments

**_2022年2月_**_奥林巴斯，一家开发和分销医疗和外科手术突破性解决方案的领导者，宣布其CELERISTM一次性鼻窦清创系统已获得FDA批准，并将很快上市。CELERIS系统旨在在一般耳鼻喉科和鼻窦/鼻科手术中切割、凝固、清创和去除薄骨和软组织。_

**_2021年8月_**_当单独使用鼻用皮质类固醇（INC）不足以解决18岁及以上患者的重度慢性鼻窦炎伴鼻息肉时，欧洲委员会（EC）已批准使用Xolair（奥马珠单抗）作为辅助治疗。_

**_2021年7月_**_根据葛兰素史克（GSK）的说法，美国食品药品监督管理局（FDA）已批准Nucala（美泊利单抗）作为治疗慢性鼻窦炎和鼻息肉患者的新适应症。这是针对白介素-5（IL-5）靶向单克隆抗体美泊利单抗的新适应症。_

## Report Scope

| MARKET SIZE 2024 | 2.319(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 2.48(USD Billion) |
| MARKET SIZE 2035 | 4.842(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 6.92% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | GlaxoSmithKline (GB), Sanofi (FR), Bayer (DE), Merck & Co. (US), AstraZeneca (GB), Novartis (CH), Teva Pharmaceutical Industries (IL), Johnson & Johnson (US), AbbVie (US) |
| Segments Covered | Treatment, End-Users, Diagnosis, Region |
| Key Market Opportunities | Advancements in telemedicine enhance access to treatment for The Global Acute Sinusitis. |
| Key Market Dynamics | Rising demand for innovative therapies drives competition and influences treatment protocols in the acute sinusitis market. |
| Countries Covered | North America, Europe, APAC, South America, MEA |

## Frequently Asked Questions

**Q: What is the projected market valuation of The Global Acute Sinusitis by 2035?**
A: The projected market valuation for The Global Acute Sinusitis is 4.842 USD Billion by 2035.

**Q: What was the market valuation of The Global Acute Sinusitis in 2024?**
A: The overall market valuation was 2.319 USD Billion in 2024.

**Q: What is the expected CAGR for The Global Acute Sinusitis during the forecast period 2025 - 2035?**
A: The expected CAGR for The Global Acute Sinusitis during the forecast period 2025 - 2035 is 6.92%.

**Q: Which companies are considered key players in The Global Acute Sinusitis?**
A: Key players in the market include GlaxoSmithKline, Sanofi, Bayer, Merck & Co., AstraZeneca, Novartis, Teva Pharmaceutical Industries, Johnson & Johnson, and AbbVie.

**Q: What segment generated the highest revenue in the treatment category for The Global Acute Sinusitis?**
A: In the treatment category, Nasal Corticosteroids generated the highest revenue, with a valuation of 1.442 USD Billion projected.

**Q: How much is the Hospitals & Clinics segment expected to be valued at by 2035?**
A: The Hospitals & Clinics segment is expected to reach a valuation of 2.883 USD Billion by 2035.

**Q: What is the projected valuation for the Allergy Testing segment by 2035?**
A: The Allergy Testing segment is projected to be valued at 1.042 USD Billion by 2035.

**Q: What is the expected growth trend for the Decongestants segment in The Global Acute Sinusitis?**
A: The Decongestants segment is expected to grow, with a projected valuation of 0.964 USD Billion by 2035.

**Q: What is the anticipated market performance for Imaging Tests in the diagnosis segment?**
A: The Imaging Test segment is anticipated to reach a valuation of 1.2 USD Billion by 2035.

**Q: How does the revenue from Antibiotics compare to other treatment options in the market?**
A: The revenue from Antibiotics is projected to be lower than other treatment options, with a valuation of 0.242 USD Billion by 2035.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/acute-sinusitis-market-5827*